Premium
P2‐227: Cross‐vendor implementation and test‐retest analysis of ADNI2 functional MRI (fMRI) and diffusion tensor imaging (DTI) sequences for multicenter clinical trials in Alzheimer's disease
Author(s) -
Marais Lea,
Perlbarg Vincent,
Poupon Cyril,
Thoprakarn Urielle,
Pinsard Basile,
Mangin JeanFrançois,
Golay Xavier,
Barker Gareth,
Hajnal Joseph,
Hill Derek,
Schwarz Adam
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.934
Subject(s) - diffusion mri , default mode network , splenium , functional magnetic resonance imaging , corpus callosum , neuroimaging , alzheimer's disease neuroimaging initiative , statistical parametric mapping , medicine , resting state fmri , magnetic resonance imaging , psychology , neuroscience , alzheimer's disease , disease , pathology , radiology
Strong evidence of neurobiological effects in clinical trials could facilitate the development of new treatments for Alzheimer’s disease. It is expected that cohorts of ~100 prodromal subjects per arm are required to obtain significant results with both vMRI and more recently developed methods such as Diffusion Tensor Imaging (DTI) and resting state functional Magnetic Resonance Imaging (rs-fMRI). For time-efficient trial execution, multi-center studies are required to provide rapid enrollment, however the collection of robust data across different scanner types and is essential. The second phase of the Alzheimer’s Disease Neuroimaging Initiative (ADNI-2) has established 3T DTI and rs-fMRI sequence parameters for GE and Philips systems only, respectively. Our objective was to implement these sequences on Philips, Siemens, and GE scanners and to evaluate their consistency prior to their use in a multi-center clinical trial.